Randomised controlled trialcited by the Tayebat archiveabstract only checked A-ODD-08 standard review
Saxagliptin heart safety trial
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Overview
Scirica BM et al.. N Engl J Med 2013 · PMID 23992601 · DOI 10.1056/NEJMoa1307684
No effect on heart attacks or strokes, but more heart failure hospitalisations (3.5% vs 2.8%, i.e. 0.7 percentage points).
Does the study support the specific claim? Partly · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
CV safety/efficacy of saxagliptin
- How was the study done?
Double-blind placebo-controlled CV outcome RCT (SAVOR-TIMI 53)
- How many people, animals or samples were studied?
16,492; Type 2 diabetes with or at risk for CV events
- What was actually found?
HR 1.00 primary; HF HR 1.27.
- How large was the observed effect?
HR 1.27 HF
- What do the results mean in everyday life?
Avoid saxagliptin in heart failure risk.
- What are the study's limitations?
Short follow-up; Industry funded
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
Multinational/US/UK data; transferable to EU practice.
- What can explicitly not be concluded from this study?
Class-wide harm.
Scientific in-depth review
1. Full reference
- Authors
- Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators
- Journal
- N Engl J Med
- Year
- 2013
- Identifier
- PMID 23992601 DOI 10.1056/NEJMoa1307684
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Funded by AstraZeneca and Bristol-Myers Squibb.
2. Research question
CV safety/efficacy of saxagliptin
3. Study design and population
- Study design
- Randomised controlled trial – Double-blind placebo-controlled CV outcome RCT (SAVOR-TIMI 53)
- Population
Type 2 diabetes with or at risk for CV events
- Country
International
- Period
Median 2.1 years
- Sample size
16,492
- Inclusion and exclusion criteria
As described in the abstract; details not available in abstract.
4. Methods and endpoints
- Exposure / intervention
Saxagliptin
- Comparator
Placebo
- Endpoints
CV death, MI, ischaemic stroke
- Statistical methods
Cox; superiority and non-inferiority
5. Actual results
- Results
Primary 7.3% vs 7.2% (HR 1.00, 0.89-1.12). HF hospitalisation 3.5% vs 2.8% (HR 1.27, 1.07-1.51). Acute pancreatitis 0.3% vs 0.2%.
- Absolute risks
HF hospitalisation +0.7 percentage points (3.5% vs 2.8%; difference calculated).
- Authors' conclusion
Saxagliptin did not increase or decrease ischaemic events; HF hospitalisation increased.
6. Strengths
- Large blinded RCT
7. Weaknesses
- Short follow-up
- Industry funded
8. Risk of bias
- Orienting tool
- RoB 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
Blinded, adjudicated.
9. Assessment of the statistical interpretation
Precise neutral primary; HF signal.
10. Relevance to the specific claim
Supports C-ODD-05; limits C-ODD-04.
11. Independent contrary findings
12. Transferability to Germany and Europe
Multinational/US/UK data; transferable to EU practice.
13. Overall methodological judgement
Neutral CV with HF signal specific to saxagliptin.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | high |
| Directness | direct |
| Reproducibility | partly replicated |
| Consistency with the overall evidence | mixed |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | essentially correct but incomplete |
14. Open questions
None beyond those stated.
15. Linked fact checks
- Injectable diabetes and weight-loss drugs (GLP-1 receptor agonists) can trigger pancreatitis and cysts. – Studies contradicting or limiting the claim
- Every major class of glucose-lowering drug (metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists) carries a documented signal of serious harm in the peer-reviewed literature. – Studies supporting the claim
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
Listed in the archive bibliography for 'oral-diabetes-drugs' without its own interpretation; used as support for the claim that every drug class carries documented harm.
- A. What was actually studied?
CV safety/efficacy of saxagliptin
- B. What did the authors find?
HR 1.00 primary; HF HR 1.27.
- C. What conclusions do the authors themselves draw?
Saxagliptin did not increase or decrease ischaemic events; HF hospitalisation increased.
- D. What does the archive derive from it?
Support for DPP-4 harm (heart failure).
- E. Is this derivation scientifically justified?
Justified for HF signal; archive omits neutral ischaemic outcomes and similar pancreatitis rates.
- Adequacy of the interpretation (by the archive)
- essentially correct but incomplete